TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: GlobeNewswire
SAN DIEGO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-travere-therapeutics-inc-investigation-tvtx.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its executives made materially false and/or misleading statements and/or omitted material information regarding Travere’s business and operations. ABOUT ROBBINS
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (TVTX) had its price target lowered by JPMorgan Chase & Co. from $44.00 to $41.00. They now have an "overweight" rating on the stock.MarketBeat
- Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli [Yahoo! Finance]Yahoo! Finance
- Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics, Inc. (TVTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]Seeking Alpha
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/18/26 - Form 4
- 3/16/26 - Form 144
- TVTX's page on the SEC website